Journal
ACS INFECTIOUS DISEASES
Volume 5, Issue 5, Pages 713-724Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.8b00337
Keywords
hepatitis B virus; HBV core protein; HBcAg; capsid assembly; capsid assembly modulators (CAMs); antiviral therapy; clinical trials
Categories
Funding
- National Science Foundation of Shanghai [DFG TRR60]
- [17ZR1436400]
Ask authors/readers for more resources
On the basis of the recent advance of basic research on molecular biology of hepatitis B virus (HBV) infection, novel antiviral drugs targeting various steps of the HBV life cycle have been developed in recent years. HBV nucleocapsid assembly is now recognized as a hot target for anti-HBV drug development. Structural and functional analysis of HBV nucleocapsid allowed rational design and improvement of small molecules with the ability to interact with the components of HBV nucleocapsid and modulate the viral nucleocapsid assembly process. Prototypes of small molecule modulators targeting HBV nucleocapsid assembly are being preclinically tested or have moved forward in clinical trials, with promising results. This Review summarizes the recent advances in the approach to develop antiviral drugs based on the modulation of HBV nucleocapsid assembly. The antiviral mechanisms of small molecule modulators beyond the capsid formation and the potential implications will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available